Overcoming Challenges in Mechanical Circulatory Support: A Guide for Hematologists
Mechanical circulatory support (MCS) devices can lead to hemostatic events, making it crucial to include a hematologist on a patient’s MCS management team.
General Hematology
GENERAL HEMATOLOGY
FEATURE
LATEST NEWS
Quantifying Adherence to Mucormycosis Treatment Guidelines in Patients With Hematologic Malignancies
Adhering to mucormycosis treatment guidelines may be difficult for physicians because of the complexity of the disease.
Managing Neutropenic Sepsis in Patients With Cancer
Researchers found no evidence that neutropenic and non-neutropenic patients with sepsis should be treated differently.
Vancomycin-Resistant Enterococcal Bacteremia Linked to Increased Mortality After HSCT
Vancomycin-resistant Enterococcus bacteremia was associated with poorer outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
No Cases of Latent Tuberculosis Reactivation Seen Following Hematopoietic Cell Transplantation
Risk for developing active tuberculosis has not been previously assessed in patients undergoing hematopoietic cell transplantation.
Increased Sirolimus Serum Concentration Associated With Decreased Cytomegalovirus DNAemia
Sirolimus treatment of patients undergoing allogeneic hematopoietic stem cell transplantation may prevent cytomegalovirus infection.
Novel Risk Score for Progression of Rhinovirus Infection in Hematopoietic Cell Transplantation Recipients
The risk factors of human rhinovirus lower respiratory tract infection following hematopoietic cell transplantation are not well known.
Identifying Risk Factors for Cytomegalovirus Antigenemia in Pediatric Patients
Researchers assessed risk factors for cytomegalovirus antigenemia in pediatric patients.
Levofloxacin Prophylaxis May Help Prevent Infections After Autologous Stem Cell Transplant
Patients undergoing autologous stem cell transplant are at increased risk for central line-associated bloodstream infections.
T-Cell Lymphopenia Is Associated With Platelet Donation Frequency
Researchers assessed a possible association between plateletpheresis and lymphopenia when 2 platelet donors were found to have low CD4+ T-lymphocyte counts.
Single-Allele Mismatch May Decrease Non-Relapse Mortality in Unrelated Bone Marrow Transplantation
A single-allele mismatch was associated with decreased risk of non-relapse mortality and overall mortality compared with a single-antigen mismatch.
Hemochromatosis Penetrance Decreased Over Time in French Cohort
Though patients tended to be older at diagnosis, the severity of genetic hemochromatosis has decreased over time.
Incidence and Prognostic Value of Cytogenetic Abnormalities in Systemic Mastocytosis
The prognostic value of karyotype in systemic mastocytosis, especially in the presence of adverse mutations, is unclear.
Intravenous Immunoglobulin Associated With Hemolytic Anemia in Kawasaki Disease
Kawasaki is a rare hematologic disease that occurs in fewer than 20,000 patients in the United States annually.
Ruxolitinib Plus Azacitidine May Benefit Patients With Myelofibrosis
The combination of the 2 drugs seems to display synergistic effects.
Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.
Palliative Issues Inadequately Addressed Among Hospitalized Cancer Patients
Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.
Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
First Generic Alternative for Mephyton Now Available
Amneal’s generic product is available in a 5mg strength tablet supplied in 100-count bottles.
Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent
Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.
Patients Identify Critical Elements of Support in Hematologic Cancers
A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.
Pacritinib May Benefit Some Patients With Myelofibrosis
Researchers evaluated whether pacritinib would improve SVR and TSS compared with the best available therapy, including ruxolitinib.
Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
A retrospective chart study demonstrated the effectiveness of fosfomycin as an antibacterial prophylaxis for febrile neutropenia in patients with hematologic cancer.
PAH Long-Term Survival Predicted by Reliable Risk Calculator
Researchers examined the effect of riociguat compared with placebo on the REVEAL risk score and long-term outcomes for pulmonary arterial hypertension.
Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety.
Vemurafenib Granted FDA Approval as First Drug to Treat Erdheim-Chester Disease
Indications for vemurafenib are expanded to include BRAF V600 mutation-positive Erdheim-Chester disease, an extremely rare non-Langerhans cell histiocytosis. FDA approval is based on results from the phase 2 VE-BASKET study.
FDA Approves Vemurafenib for Erdheim-Chester Disease
This is the first-ever drug approval for the blood cancer, which, although rare, carries a poor prognosis.
Momelotinib vs Ruxolitinib for Myelofibrosis: Phase 3 Trial Yields Mixed Results
Researchers compared the safety and efficacy of ruxolitinib vs momelotinib, a selective JAK1/2 inhibitor, among JAK inhibitor-naïve patients with myelofibrosis.
FDA Expands Approval for Ibrutinib To Include Chronic Graft vs Host Disease
The FDA expanded the indications of ibrutinib to include the treatment of adult patients with cGVHD who have failed at least one prior therapy.
Rare Case of Langerhans Cell Histiocytosis With Prior ITP Highlights Diagnostic Challenge for Clinicians
A rare case of Langerhans cell histiocytosis (LCH) in a patient with idiopathic thrombocytopenic purpura (ITP) highlights the difficulty in diagnosing LCH.
First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Momelotinib vs Ruxolitinib for Patients With Myelofibrosis
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
Factors Associated With Hospice Enrollment Among Patients With Hematologic Cancers
Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.
New Gene Mutations Associated with Erdheim-Chester Disease Could Improve Treatment Options
BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.
Hematologic Oral Chemotherapy Clinic Reduces Emergency Department Visits
A hematologic multidisciplinary oral chemotherapy clinic established at a community hospital identified adverse events early and reduced ED visits.
Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
Simtuzumab is well-tolerated but has inconsistent clinical benefit for patients with myelofibrosis.
Pacritinib More Effective at Spleen Volume Reduction Than Best Available Therapy in Myelofibrosis
Treatment with the multityrosine kinase inhibitor pacritinib resulted in a significant reduction in spleen volume compared with best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia, according to a study presented at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition. For the phase 3 PERSIST-2 study (ClinicalTrials.gov identifier: NCT02055781), investigators…
Pomalidomide + Dexamethasone Rescue Active in AL Amyloidosis
Rescue therapy with pomalidomide in combination with dexamethasone is a rapidly active regimen in amyloid light-chain (AL) amyloidosis.
Want to read more?
Please login or register first to view this content.
Next post in General Hematology
